Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
January 30, 2024
Since its launch in 2000, Gavi, the Vaccine Alliance, has leveraged three primary levers to expand equitable vaccine access in lower-income countries. First, Gavi supports introductions of new and underused vaccines. Second, Gavi helps scale equitable immunization coverage rates. Third, Gavi uses an...
Blog Post
December 14, 2023
Harsh fiscal prospects and broader shifts in the health landscape are creating challenges for Gavi’s approach to country eligibility and transition. To date, Gavi’s income-based eligibility model has functioned well during periods of sustained growth in low- and middle-income countries and has helpe...
Blog Post
December 04, 2023
In the aftermath of the COVID-19 pandemic, Gavi faces an unprecedented situation. Billions of dollars that it raised back in 2022 for COVAX—the global effort to provide COVID-19 vaccines to lower-income countries—remain unspent. These resources are substantial, exceeding the entire annual budget of ...
Blog Post
December 01, 2023
When Gavi’s board meets in Accra, Ghana, next week, advancing discussions on a new five-year strategic period, known as “Gavi 6.0,” will be a top agenda item. But conversations about Gavi’s future direction are also taking place against the backdrop of a leadership transition and a rapidly changing ...
Blog Post
November 15, 2023
One of the most salient lessons from the pandemic is the need to diversify manufacturing capabilities and bolster supply resilience to avoid a repeat of the slow and inequitable vaccine roll out in African countries. To turn this lesson into action, the Gavi Secretariat is rapidly advancing plans fo...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...